Effect of Parnfuti in prevention of stone formation and reduction of stone size in patients of renal stone disease.
- Conditions
- Health Condition 1: null- Renal stone size between 8 mm and 11 mm
- Registration Number
- CTRI/2016/11/007425
- Lead Sponsor
- Department of Pharmacology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 100
•Patients of both the genders aged > 18 Years of age.
•Renal stone >8 mm and <11 mm (single or multiple) visible on USG.
•Total leucocyte count and Serum creatinine level within normal range.
•Ability to tolerate oral fluids and Analgesic drugs.
•Patientâ??s willingness for follow up.
•Patient not on contraceptives or calcium therapy.
•Patient not involved in any other clinical trial in last 30 days.
•Patient not having Dementia or other cognitive disorders prohibiting informed consent.
•Children and elderly patient.
•Pregnancy or planning for pregnancy.
•Lactating mother.
•History of any substance abuse.
•Active urinary tract infection
•Obstructive Uropathy, Benign prostatic hyperplasia or hydronephrosis.
•Any malignancy.
•People leaving with HIV AIDS (PLHA).
•Hepatitis-B, Hepatitis-C.
•Person with single Kidney.
•Previous renal surgery.
•Cardiac diseases, Hypertension or Patient on diuretics.
•Metabolic disorders (Hyper thyroidism, Hyper para thyroidism)
•Known case of Gout.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Renal function test <br/ ><br>X-ray KUB <br/ ><br>USG KUB <br/ ><br>Urine testsTimepoint: 1 month, <br/ ><br>2 month, <br/ ><br>3 month. <br/ ><br>Urine tests
- Secondary Outcome Measures
Name Time Method need of rescue treatment, <br/ ><br>Safety dataTimepoint: Any time during study, and at the time of follow up at <br/ ><br>1 month, <br/ ><br>2 month, <br/ ><br>3 month.